参考文献/References:
[1]Yellon DM,Hausenloy DJ.Myocardial reperfusion injury[J].N Engl J Med,2007,357(11):1121-1135.
[2]Pagliaro P,Moro F,Tullio F,et al.Cardioprotective pathways during reperfusion: focus on redox signaling and other moda lities of cell signaling[J].Antioxid Redox Signal,2011,14(5):833-850.
[3]Hausenloy DJ,Yellon DM. Myocradial ischemia-Reperfusion injury:a neglected therapeutic target[J]. Clin Invest ,2013,123(1):92-100.
[4]Hausenloy DJ,Yellon DM. Ischaemic conditioning and reperfusion injury[J]. Nat Rev Cardiol ,2016,13(4):193-209.
[5]Galluzzi L,Vitale I,Aaronson SA,et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death ,2018[J].Cell Death Differ,2018,25(3):486-541.
[6]Tonnus W,Meyer C,Paliege A,et al.The pathological features of regulated necrosis[J]. J Pathol ,2019,247(5):697-707.
[7]Liang H,Liu Y.Gasdermins pore cell membrane to pyroptosis[J].Sci China Life Sci,2016,59(10):1090-1092.
[8]Shalini S,Dorstyn L,Dawar S,et al.Old,new and emerging functions of caspases[J].Cell Death Differ,2015,22(4) :526-539.
[9]Grootjans S,Vanden Berghe T.Initiation and execution mechanisms of necroptosis:an overview[J].Cell Death Differ,2017,24(7):1184-1195.
[10]Cookson BT, Brennan MA. Pro-inflammatory programmed cell death[J].Trends Microbiol,2001,9(3):113-114.
[11]Galluzzi L,Vitale I,Abrams JM,et al.Molecular definitions of cell death subroutines:recommendations of the nomenclature committee on cell death 2012[J].Cell Death Differ,2012,19(1):107-120.
[12]Toldo S,Abbate A. The NLRP3 inflammasome in acute myocardial infarction[J]. Nat Rev Cardiol,2018,15(4):203-214.
[13]Man SM,Karki R,Kanneganti TD.Moleular mechanisms and functions of pyroptosis,inflammatory caspases and inflammasomes in infectious diseases[J].Immunol Rev,2017,277(1):61-75.
[14]Shi J,Zhao Y,Wang K,et al .Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death[J]. Nature,2015,526(7575):660-665.
[15]Gong W,Shi Y,Ren J.Research progresses of molecular mechanism of pyroptosis and its related Diseases[J]. Immunobiology,2020,225(2):151884.
[16] Broz P,Pelegrin P,Shao F. The gasdermin,a protein family executing cell death and inflammation[J]. Nat Rev Immunol,2020,20(3):143-157.
[17]Kesavardhana S,Mailreddi RKS,Kanneganti TD. Caspases in the cell death,inflammation,and gasdermin-induced pyroptosis[J]. Annu Rev Immunol,2020 ,38:567-595.
[18]Zhang T,Zhang Y,Cui M,et al. CaMKⅡ is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis[J]. Nat Med ,2016,22(2): 175-182.
[19]Jia C,Chen H,Zhang J,et al.Role of pyroptosis in cardiovascular diseases[J].Int Immunopharmacol,2019,67:311-318.
[20]Choi ME,Price DR,Ryter SW,et al.Necroptosis:a crucial pathogenic mediator of human disease [J].JCI Insight,2019,4(15):e128834.
[21]Chen J,Kos R,Garssen J,et al.Molecular insights into the mechanism of necroptosis:the necrosome as a potential therapeutic target[J].Cells,2019,8(12):1486.
[22]Dmitriev YV,Minasian SM,Demchenko EA,et al. Study of cardioprotective effects of necroptosis inhibitors on isolated rat heart subjected to global ischemia-reperfusion[J]. Bull Exp Biol Med,2013,155(2): 214-217.
[23] Luedde M,Lutz M,Carter N,et al. RIP3,a kinase promoting necroptotic cell death,mediates adverse remodelling after myocardial infarction[J]. Cardiovasc Res,2014,103(2):206-216.
[24]Cruz SA,Qin Z,Stewart AFR,et al.Dabrafenib,an inhibitor of RIP3 kinase-dependent necroptosis,reduces ischemic brain injury[J]. Neural Regen Res,2018,13(2):252-256.
[25]Moerke C,Bleibaum F,Kunzendorf U ,et al. Combined knockout of RIPK3 and MLKL reveals unexpected outcome in tissue injury and inflammation[J]. Front Cell Dev Biol,2019,7:19.
[26]Zhou W,Chen C,Chen Z,et al.NLRP3:a novel mediator in cardiovascular disease[J]. Immunol Res,2018 ,2018:5702103.
[27]Sandanger ?,Gao E,Ranheim T,et al.NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective[J]. Biochem Biophysl Res Commun ,2016,494(4):1012-1020.
[28]Toldo S,Marchetti C,Mauro AG,et al. Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia reperfusion in the mouse[J].Int J Cardiol,2016,209:215-220.
[29]Deftereos S,Giannopoulos G,Angelidis C,et al.Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study[J]. Circulation,2015,132(15):1395-1403,
[30]Tardif JC,Kouz S,Waters DD,et al.Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med,2019,381(26):2497-2505.
[31]Rauf A,Shah M,Yellon DM,et al.The Role of caspase-1 in ischemia/reperfusion injury of the myocardium[J]. J Cardiovasc Pharmacol,2019,74(3):194-200.
[32]Takahashi M.NLRP3 inflammasome as a novel player in myocardial infarction[J].Int Heart J,2014,55(2):101-105.
[33]Audia JP,Yang XM,Crockett ES,et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function[J]. Basic Res Cardiol,2018,113(5):32.
[34]Ridker PM,Everett BM,Thuren T,et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.
[35]Abbate A,Kontos MC,Abouzaki NA,et al. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies)[J]. Am J Cardiol,2015,115(3):288-292.
[36]Rathkey JK,Zhao J,Liu Z,et al.Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis[J]. Sci Immunol,2018,3,eaat2738.
[37]Zhang D,Qian J,ZhangP,et al.Gasdermin D serves as a key executioner of pyroptosis in experimental cerebral ischemia and Reperfusion model both in vivo and in vitro[J].J Neurosci Res,2019,97(6):645-660.
相似文献/References:
[1]阎萌,田芳,综述,等.程序性坏死与动脉粥样硬化[J].心血管病学进展,2016,(2):139.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.011]
YAN Meng,TIAN Fang,TIAN Ye.Necroptosis and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(12):139.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.011]
[2]张馨月 涂荣会.Toll样受体与心肌缺血再灌注损伤及其保护作用研究进展[J].心血管病学进展,2020,(2):172.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.018]
ZHANG Xinyue,TU Ronghui.Review Onprotective Effects of Toll-like Receptors on Myocardial Ischemia Reperfusion Injury[J].Advances in Cardiovascular Diseases,2020,(12):172.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.018]
[3]张明 王敬萍.Nur77和GRP78与糖尿病心肌缺血再灌注损伤的关系研究[J].心血管病学进展,2020,(6):571.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.003]
ZHANG Ming Wang Jingping.Relationship between Nur77 and GRP78 and Myocardial Ischemia-reperfusion Injury in Diabetic Patients[J].Advances in Cardiovascular Diseases,2020,(12):571.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.003]
[4]韩敏 朱兵 余嘉清 马依彤.程序性细胞死亡与心肌缺血再灌注损伤[J].心血管病学进展,2020,(10):1069.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.017]
HAN MinZHU BingYU JiaqingMA Yitong. Programmed Cell Death and Myocardial Ischemic Reperfusion Injury[J].Advances in Cardiovascular Diseases,2020,(12):1069.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.017]
[5]彭石 马茜钰 张丹 张兆元 张锦.铁死亡在心肌缺血再灌注损伤中的作用及靶向治疗研究进展[J].心血管病学进展,2022,(4):357.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.017]
PENG Shi,MA Qianyu,ZHANG Dan,et al.Role and Targeted Treatment of Ferroptosis?n Myocardial Ischemia Reperfusion Injury[J].Advances in Cardiovascular Diseases,2022,(12):357.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.017]
[6]叶宇恒 钱玲玲 王如兴 李库林.心肌缺血再灌注损伤中铁死亡的调控机制研究进展[J].心血管病学进展,2023,(5):416.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.008]
YE Yuheng,QIAN Lingling,WANG Ruxing,et al.Regulatory Mechanisms of Ferroptosis in Myocardial Ischemia Reperfusion Injury[J].Advances in Cardiovascular Diseases,2023,(12):416.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.008]
[7]李秋 李蔚华.TRIM蛋白家族在心肌缺血再灌注损伤中的研究进展[J].心血管病学进展,2023,(8):743.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.016]
LI Qiu,LI Weihua.Research Progress of TRIM Family in Myocardial Ischemia Reperfusion Injury[J].Advances in Cardiovascular Diseases,2023,(12):743.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.016]
[8]李俊霖 韩虎魁 程攀科 李刚 陶剑虹.Foxp3+调节性T细胞与心肌缺血再灌注损伤概述[J].心血管病学进展,2023,(9):832.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.015]
LI Junlin,HAN Hukui,CHENG Panke,et al.Overview of Foxp3+ Regulatory T Cells and Myocardial Ischemia R eperfusion Injury[J].Advances in Cardiovascular Diseases,2023,(12):832.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.015]
[9]冉黔松 周厚荣.长链非编码RNA调节自噬在心肌缺血再灌注损伤中的研究进展[J].心血管病学进展,2024,(3):238.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.011]
RAN Qiansong ZHOU Hourong.Long Non-Coding RNA Regulating Autophagy in Myocardial Ischemia-Reperfusion Injury[J].Advances in Cardiovascular Diseases,2024,(12):238.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.011]
[10]热伊莱·开赛尔 谢翔.琥珀酸在心肌缺血再灌注损伤中的研究进展[J].心血管病学进展,2024,(8):722.[doi:10.16806/j.cnki.issn.1004-3934.202.08.011]
Reyilai·Kaisaier,XIE Xiang.Succinic Acid and Myocardial Ischemia-Reperfusion Injury[J].Advances in Cardiovascular Diseases,2024,(12):722.[doi:10.16806/j.cnki.issn.1004-3934.202.08.011]
[11]郭双 吕勃.细胞凋亡和程序性坏死在心肌缺血再灌注损伤中的作用研究[J].心血管病学进展,2022,(12):1148.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.020]
GUO Shuang L YU Bo.The Role of Apoptosis and Necroptosis in Myocardial Ischemia-Reperfusion Injury[J].Advances in Cardiovascular Diseases,2022,(12):1148.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.020]